All News
EULAR 2021 - Day 2 Podcasts
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com
Listen by Clicking below:
Read Article
New insights in RA-ILD therapeutics
RA associated ILD (RA-ILD) is the most common extra-articular manifestation in RA. Its prevalence varies considerably, ranging from 5% to 30%, and is often underestimated since patients only become symptomatic or display abnormalities on chest X-Ray at a late stage of disease, leading to subsequent delay in diagnosis. In this context, several groups advocate for an earlier and more precise detection, using high resolution chest computed tomography (HRCT), which is the most sensitive for pre-clinical RA-ILD diagnosis.
But why would we want to diagnose early a manifestation that we cannot treat?
Turning the Corner on CV Risk in Rheumatoid Arthritis
Cardiovascular (CV) disease remains the leading cause of mortality in rheumatoid arthritis (RA). A number of studies progressed our knowledge in the session Rheumatoid arthritis - comorbidity and clinical aspects – I on Thursday at EULAR 2021.
Read Article
Metabolomic profiling for PsA showed vLDL, triglycerides; apolipoprotein B, glycoprotein acetylene associated with increased CV events…
Do you monitor cholesterol levels in your PsA pts?
Abs#OP0221
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2021 OP0290: Cluster analysis of APLS
4 Clusters:
⭐️ 2ndary APS, non-criteria
⭐️ ♂️ with CV risks
⭐️OB morbidity
⭐️Isolated LA +
@RheumNow
Eric Dein ejdein1 ( View Tweet)
Turning the Corner on CV Risk in Rheumatoid Arthritis by Richard Conway ( @RichardPAConway) #EULAR2021
https://t.co/S0ownscRKv https://t.co/PJODe0U6wr
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr Yoshida analyze data from US registry 40,721 RA patients. High 2.11 [1.13, 3.96] and moderate 1.97 [1.13, 3.43] CDAI associated w/ > HR of major adverse CV events. HRs decrease during follow up.
Tight and early disease control reduces CV burden!
#EULAR2021 @Rheumnow #OP0101 https://t.co/A0ZYE4v8uf
Aurelie Najm AurelieRheumo ( View Tweet)
In 16,448 RA from ACR’s RISE registry: no difference in disease activity TNFi and non-TNFi at 12 months. Stratified analysis: ⬆️disease activity for TNFi vs. non TNFi in patients of Black and Asian ethnicity. To be confirmed in independent cohorts.
#EULAR2021 @Rheumnow #OP0117 https://t.co/7bFnOKR9uz
Aurelie Najm AurelieRheumo ( View Tweet)
Can we predict pre-clinical RA-ILD?
@Juge_P_A ESPOIR cohort. model w/ 4 variables: male gender, older age @ diag, mean DAS-28 over follow-up and MUC5B variant ▶️ preclinical ILD after 13 years of RA w/ AUC=0.82 CI 95% (0.72-0.91) (Sens 80%, Spe 56%)
#POS0095 @Rheumnow #EULAR2021 https://t.co/bPyidNhNuO
Aurelie Najm AurelieRheumo ( View Tweet)
Very informative #EULAR2021 WIN session on MIS-C @EULAR_org
👉 Steroids early
👉 IVIg in all
👉 anticoagulant use remains variable
#Coronary aneurysms
✅ occur during acute phase in MIS-C and improve with treatment
✅ occur in the late/convalescent phase of #Kawasaki disease https://t.co/Ff3rX6u5VK
Ashima Makol MD AshimaMakol ( View Tweet)
Do we need to monitor #ECG in patients on #HCQ and #polypharmacy? Dr Antivalle reported ⬆️QTc interval in HCQ vs controls. Only 3/132 was above ULN in HCQ group though. Importantly,⬆️QTc was noted more in HCQ + co-meds (e.g. PPI) #EULAR2021 #POS0090 @RheumNow https://t.co/1Ui4MghqIk
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
How common is RA ILD? @RheumNow #EULAR2021 @eular_org
Janet Pope Janetbirdope ( View Tweet)
Leave my MTX alone says pt & #rheumatologist if pt has chronic ILD. Acute pneumonia from MTX is NOT chronic ILD in RA @RheumNow @eular_org #EULAR2021 #BoehringerIngelheim RA ILD silent killer symposium https://t.co/IQTINuUpVq
Janet Pope Janetbirdope ( View Tweet)
RA ILD will kill pts esp UIP pattern and extent & presence of honeycombing on HRCT. Think about it esp if older pt #EULAR2021 #BoehringerIngelheim symposium @RheumNow @eular_org https://t.co/be2Z7KMqpg
Janet Pope Janetbirdope ( View Tweet)
MUC5B promoter variant is associated with interstitial lung disease.
Interactions with:
👉rheumatoid arthritis
👉 age
👉 sex
Check this Finnish biobank study of 250,000 individuals presented by Antti Palömaki at the Plenary Abstracts Session Wed 02/06 16:15
>LC
ARD & RMD Open ARD_BMJ ( View Tweet)
Dr Lam presenting data on early RA and matched controls. T2T strategy led to no increased CV event risk over 5 years. Longer remission duration protective, higher baseline HAQ associated with higher risk @RheumNow #EULAR2021 Abstr#OP0103 https://t.co/MZdEoyWI64
Richard Conway RichardPAConway ( View Tweet)
Using data of the E3N prospective observational study - including 98995 women - passive smoking in childhood or adulthood could be found as risk factor for #RA and potentially earlier onset
#OP0012 #EULAR2021 @RheumNow https://t.co/58DJ8lZzfV
Paul Studenic Stiddyo ( View Tweet)
Don’t forget to detect cardiac abnormalities in your #RA and #PsA patients! Systematic transthoracic echocardiogram show higher prevalence of diastolic dysfunction, mild mitral and pulmonary valve regurgitation vs. matched controls. #EULAR2021 @RheumNow #POS1392 https://t.co/UsvbEKBRUY
Aurelie Najm AurelieRheumo ( View Tweet)
Dr Palomäki on influence of MUC5B promotor variant on ILD risk in RA and non-RA. Lifetime risk ILD 14.5% for RA+MUC5B+, 5.2% for RA+MUC5B-, 3.9% RA-MUC5B+ 1.3% RA-MUC5B- @RheumNow #EULAR2021 Abstr#OP0007 https://t.co/BnexQE1Pw9
Richard Conway RichardPAConway ( View Tweet)
Dr. G Robinson Abstr#OP0013 on sex link b/t autoimmune & CV risk
👉Hormones drive funx change in Treg transciptome
👉anti-inflamm Tregs⬆️in males
👉Tregs are more suppressive in males
👉Treg transciptome profile altered b/t males & females in autoimmunity #EULAR2021 @rheumnow https://t.co/p4Awfu2hiK
k dao KDAO2011 ( View Tweet)
